Consensus Elusive On Design Of Breast Cancer Ablation Registry
This article was originally published in The Gray Sheet
Executive Summary
Cost and patient participation will probably be major impediments in developing a registry of breast cancer ablation clinical trials, according to stakeholder comments to FDA